Noah Stansfield

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Instil Bio, ITIL-306’s developer, expects to present initial data from the phase 1 trial’s dose escalation cohorts this year.

Some patients previously treated with GNT-003 were able to maintain the stoppage of phototherapy for at least 1 year.

No serious adverse events related to the gene therapy have been reported.

The company expects to provide initial data from the trial in the second half of this year.

Promising results were previously reported from a proof-of-concept study involving 8 patients.

The first patient dosed in the study experienced a case of prolonged pancytopenia that has required ongoing transfusion and growth factor support.

Initial data from the trials of HMI-103 and HMI-203 are expected in 2023.

Allocetra previously demonstrated efficacy in a phase 1b trial for patients with sepsis.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT103A is currently being evaluated in multiple clinical trials in China.

The company is seeking out other companies to continue development of its autologous CAR-T platform.

The CR was achieved at 1-month post-treatment.

The trial will incorporate findings from CYGNET, a natural history study designed to assess the disease progression of AMN.

NFS-02 previously received orphan drug designation from the FDA in January of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The agency granted OCU400 orphan drug designation for additional indications and agreed to a phase 3 trial design for NeoCart.

No dose-limiting toxicities or treatment-related serious adverse events were reported among 24 treated patients.

The hold was originally placed in December 2021 and was related to a case of persistent, non-transfusion-dependent anemia in a pediatric patient.

No treatment-related serious adverse events were reported.

Four of 17 patients who received UCART123v1.2 showed clinical benefit.

The complete metabolic response rate was 70% 3 months after infusion.

100% of patients who achieved transfusion independence reported an overall benefit from treatment.

Among the 38 patients now dosed and evaluable, the ORR remains at 100%.

A complete response rate of 67% was reported and no treatment-limiting toxicity occurred.

REGENXBIO expects to provide updated interim data from the trial in the first half of next year.

IN8bio intends to initiate a multicenter phase 2 clinical trial for INB-400 in glioblastoma in 2023.

The patient tolerated administration of Mylotarg after engraftment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Two of 4 evaluable patients showed stable disease in data presented at ESMO-IO 2022.